Meropenem therapy failure in Listeria monocytogenes infection

Eur J Clin Microbiol Infect Dis. 2004 Jun;23(6):484-6. doi: 10.1007/s10096-004-1135-3. Epub 2004 May 13.

Abstract

Listeria monocytogenes is highly susceptible to meropenem in vitro, but data on the efficacy of meropenem in clinical cases of listeriosis are scarce. Described here is the case of a child with aplastic anemia who acquired nosocomial listeriosis and failed to respond to initial meropenem therapy. Resolution of fever was not noted after 5 days of therapy with meropenem and, more importantly, clinical worsening was observed during this period. The patient began to improve after ampicillin was introduced to the therapeutic regimen. In total, meropenem was administered for 15 days and ampicillin for 10 days.

Publication types

  • Case Reports

MeSH terms

  • Ampicillin / administration & dosage
  • Anemia, Aplastic / diagnosis
  • Anemia, Aplastic / immunology
  • Child, Preschool
  • Cross Infection / drug therapy
  • Cross Infection / microbiology
  • Drug Therapy, Combination / administration & dosage*
  • Follow-Up Studies
  • Humans
  • Immunocompromised Host
  • Listeria monocytogenes / isolation & purification*
  • Listeriosis / diagnosis*
  • Listeriosis / drug therapy*
  • Male
  • Meropenem
  • Risk Assessment
  • Severity of Illness Index
  • Thienamycins / administration & dosage*
  • Treatment Failure

Substances

  • Thienamycins
  • Ampicillin
  • Meropenem